Immune response in COVID-19: What do we currently know?

被引:13
|
作者
Oliveira, Daniela S. [1 ]
Medeiros, Nayara I. [1 ,2 ]
Gomes, Juliana A. S. [1 ]
机构
[1] Univ Fed Minas Gerais, Lab Biol Interacoes Celulares, Dept Morfol, Inst Ciencias Biol, Belo Horizonte, MG, Brazil
[2] Fundacao Oswaldo Cruz FIOCRUZ, Imunol Celular & Mol, Inst Rene Rachou, Belo Horizonte, MG, Brazil
关键词
RESPIRATORY SYNDROME CORONAVIRUS; MERS-COV; MEMORY; SARS; REPLICATION; INFECTION; PATHOGENESIS; PATHOLOGY; CELLS; ANTIBODIES;
D O I
10.1016/j.micpath.2020.104484
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In 2002/2003 there was a pandemic denominate SARS (severe acute respiratory syndrome), caused by the SARS-CoV virus that belongs to the genera Betacoranavirus and the family Coronaviridae, generally responsible for influenza infections. In mid of 2019, a new disease by the coronavirus named by COVID-19 (SARS-CoV-2) emerged, both infections have flu symptoms, however they are infections that variable intensity, being medium to severe. In medium infections individuals have the virus and exhibit symptoms, however hospitalization is not necessary, in severe infections, individuals are hospitalized, have high pathology and in some cases progress to death. The virus is formed by simple positive RNA, enveloped, non-segmented, and presenting the largest genome of viruses constituting 32 Kb, consisting of envelope proteins, membrane, nucleocapsid and spike protein, which is essential in the interaction with the host cells. As for the origin of this virus, research has been intensified to determine this paradox and although the similarity with SARS-CoV, this virus did not has necessarily the same place of origin. As for the immune system, it is currently unknown how this new virus interacts. In this brief review, we demonstrate important considerations about the responses to this infection.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] COVID-19 and the liver: What do we know so far?
    Prashant Nasa
    George Alexander
    World Journal of Hepatology, 2021, 13 (05) : 522 - 532
  • [32] Elective procedures in times of COVID-19: ?What do we know?
    Ensuncho, Cesar
    ARCHIVOS DE MEDICINA, 2020, 20 (02): : 513 - 517
  • [33] COVID-19 and diabetes: What do we know so far?
    Gangadaran, Prakash
    Padinjarathil, Himabindu
    Rajendran, Shri Hari Subhashri
    Jogalekar, Manasi P.
    Hong, Chae Moon
    Aruchamy, Baladhandapani
    Rajendran, Uma Maheswari
    Gurunagarajan, Sridharan
    Krishnan, Anand
    Ramani, Prasanna
    Subramanian, Kavimani
    EXPERIMENTAL BIOLOGY AND MEDICINE, 2022, 247 (15) : 1330 - 1334
  • [34] COVID-19 and Myocarditis: What Do We Know So Far?
    Pirzada, Ashar
    Mokhtar, Ahmed T.
    Moeller, Andrew D.
    CJC OPEN, 2020, 2 (04) : 278 - 285
  • [35] COVID-19 and the liver: What do we know so far?
    Nasa, Prashant
    Alexander, George
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (05) : 522 - 532
  • [36] COVID-19 vaccines: what do we know so far?
    Dhillon, Paraminder
    Altmann, Daniel
    Male, Victoria
    FEBS JOURNAL, 2021, 288 (17) : 4996 - 5009
  • [37] Breast Milk and COVID-19: What Do We Know? COMMENT
    Kimberlin, David W.
    Puopolo, Karen M.
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (01) : 131 - 132
  • [38] COVID-19 and the gastrointestinal tract: what do we already know?
    Machado de Almeida, Joana Ferro
    Chehter, Ethel Zimberg
    EINSTEIN-SAO PAULO, 2020, 18 : eRW5909
  • [39] What do we know about Kawasaki disease and COVID-19?
    Alberto Hernandez Arias, Jeffrey James William
    Herrera de la Hoz, Rosa Elena
    Lequerica Segrera, Pedro Luis
    ANDES PEDIATRICA, 2021, 92 (02): : 281 - 287
  • [40] COVID-19 and Anemia: What Do We Know So Far?
    Abu-Ismail, Luai
    Taha, Mohammad J. J.
    Abuawwad, Mohammad T.
    Al-Bustanji, Yaqeen
    Al-Shami, Khayry
    Nashwan, Abdulqadir
    Yassin, Mohamed
    HEMOGLOBIN, 2023, 47 (03) : 122 - 129